Reaction
T-Lymphocyte Count Decreased reporting signals
As of the last recalculation, T-Lymphocyte Count Decreased appears in 674 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 60.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alemtuzumab | 36 | 60.7 | 60.8 |
| Dolutegravir Sodium | 13 | 45.4 | 45.4 |
| Anti-Thymocyte Globulin (Rabbit) | 9 | 34.9 | 34.9 |
| Thiotepa | 9 | 29.5 | 29.5 |
| Ocrelizumab | 54 | 29.1 | 29.2 |
| Axicabtagene Ciloleucel | 8 | 25.3 | 25.3 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 14 | 24.3 | 24.4 |
| Cladribine | 7 | 22.7 | 22.7 |
| Atazanavir | 10 | 21.8 | 21.8 |
| Fingolimod Hcl | 54 | 20.9 | 20.9 |
| Lopinavir And Ritonavir | 9 | 20.8 | 20.8 |
| Emtricitabine And Tenofovir Alafenamide | 7 | 19.3 | 19.3 |
| Ozanimod Hydrochloride | 5 | 18.7 | 18.7 |
| Dalfampridine | 38 | 17.3 | 17.3 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 5 | 15.5 | 15.5 |
| Dimethyl Fumarate | 52 | 14.1 | 14.1 |
| Siponimod | 4 | 13.9 | 13.9 |
| Diroximel Fumarate | 5 | 13.0 | 13.1 |
| Ofatumumab | 13 | 12.3 | 12.3 |
| Blinatumomab | 4 | 11.9 | 11.9 |
| Cabotegravir | 3 | 11.5 | 11.5 |
| Emtricitabine And Tenofovir Disoproxil Fumarate | 13 | 9.0 | 9.0 |